Table 3.
Clinical, diagnostic tests, complications, and laboratory information of three groups of patients.
| Groups | MuSK-MG | AChR-MG | DSN-MG | P value | |
|---|---|---|---|---|---|
| (A) Clinical features | |||||
| Onset distribution | Pure ocular | 7/14 (50.0%) | 98/130 (75.4%) | 30/39 (76.9%) | 0.107 |
| Pure limb | 1/14 (7.1%) | 10/130 (7.7%) | 5/39 (12.8%) | >0.05 | |
| Pure bulbar | 3/14 (21.4%) | 6/130(4.6%) | 1/39(2.6%) | <0.05* | |
| Respiratory | 1/14 (7.1%) | 3/130 (2.3%) | - | 0.339 | |
| Oculobulbar | 2/14 (14.3%) | 13/130 (10.0%) | 3/39 (7.7%) | >0.05 | |
| Positive rate of Jolly test | 11/14 (78.6%) | 130/130 (100%) | 39/39 (100%) | <0.001*** | |
| Tongue muscle atrophy | 3/14 (21.4%) | 1/130 (0.8%) | - | 0.003** | |
| Most severe Osserman classification | I | 1/14 (7.1%) | 38/130 (29.2%) | 23/39 (59.0%) | <0.001*** |
| IIa | 1/14 (7.1%) | 20/130 (15.4%) | 4/39 (10.3%) | 0.545 | |
| IIb | 8/14 (57.1%) | 61/130 (46.9%) | 11/39 (28.2%) | 0.068 | |
| III | 1/14 (7.1%) | 8/130 (6.2%) | 1/39 (2.6%) | 0.660 | |
| IV | 3/14 (21.4%) | 3/130 (2.3%) | - | <0.05* | |
| (B) Diagnostic tests | |||||
| Neostigmine trial | 9/14 (64.3%) | 108/109 (98.2%) | 33/34 (97.1%) | <0.05* | |
| Cholinergic side effect | 7/14 (50.0%) | 2/109 (1.8%) | - | <0.001*** | |
| Decrement on RNS (3 Hz) | 8/11 (72.7%) | 65/88 (73.9%) | 16/28 (57.1%) | 0.238 | |
| (C) Coexisting other AD/Abs | |||||
| Thymic abnormalities | 1/14 (7.1%) | 58/130 (44.6%) | 10/39 (25.6%) | 0.006** | |
| Other AD | 6/14 (42.9%) | 19/130 (14.6%) | 7/39 (17.9%) | 0.030* | |
| TG/TPO Ab | 8/11 (72.7%) | 35/93 (37.6%) | 10/23 (43.5%) | >0.05 | |
Comparison of clinical, diagnostic tests, complications and laboratory examination data among the three groups was done by χ2 test or Fisher exact χ2 test.
*
indicates P < 0.05,
**
indicates P < 0.01,
***
indicates P < 0.001.
The data are shown as mean ± SD or ratio. AD, autoimmune disease; RNS, repetitive nerve stimulation; TG, thyroglobulin; TPO, thyroid peroxidase; Ab, antibody.